Scynexis News

Buy Rating Affirmed for Scynexis on Robust Financials and Promising Antifungal Pipeline

TipRanksMay 10 12:20 ET

Analysts' Top Healthcare Picks: Cormedix (CRMD), SCYNEXIS (SCYX)

TipRanksMay 10 12:15 ET

Buy Rating Affirmed for SCYNEXIS on Strong Financials and Promising Pipeline Prospects

TipRanksApr 11 11:20 ET

Buy Rating Affirmed for SCYNEXIS on Ibrexafungerp Success and Strong GSK Partnership

TipRanksApr 2 06:50 ET

SCYNEXIS Analyst Ratings

BenzingaApr 1 08:32 ET

Promising Antifungal Drug Developments Bolster Buy Rating for SCYNEXIS

TipRanksJan 31 07:05 ET

Analysts Have Conflicting Sentiments on These Healthcare Companies: SCYNEXIS (SCYX) and Kymera Therapeutics (KYMR)

TipRanksJan 3 07:01 ET

Analysts Offer Insights on Healthcare Companies: SCYNEXIS (SCYX) and Ocuphire Pharma (OCUP)

TipRanksSep 28, 2023 14:40 ET

Ladenburg Thalmann Cuts SCYNEXIS Price Target to $7.50 From $15, Maintains Buy Rating

MT NewswiresSep 25, 2023 11:26 ET

SCYNEXIS (SCYX) Receives a Buy From Ladenburg Thalmann & Co.

TipRanksSep 25, 2023 11:15 ET

SCYNEXIS (SCYX) Receives a Buy From Maxim Group

TipRanksAug 16, 2023 11:35 ET

Cantor Fitzgerald Reiterates Overweight on SCYNEXIS, Maintains $15 Price Target

BenzingaAug 15, 2023 10:29 ET

SCYNEXIS Analyst Ratings

BenzingaAug 15, 2023 10:28 ET

SCYNEXIS (SCYX) Receives a Buy From Ladenburg Thalmann & Co.

TipRanksAug 15, 2023 07:05 ET

Maxim Group Sticks to Its Buy Rating for SCYNEXIS (SCYX)

TipRanksMay 12, 2023 11:15 ET

Ladenburg Thalmann & Co. Sticks to Their Buy Rating for SCYNEXIS (SCYX)

TipRanksMay 11, 2023 07:35 ET

Guggenheim Adjusts Price Target on SCYNEXIS to $9 From $8, Maintains Buy Rating

MT NewswiresApr 3, 2023 10:12 ET

Guggenheim Maintains Buy on SCYNEXIS, Raises Price Target to $9

BenzingaApr 3, 2023 09:14 ET

Ladenburg Thalmann Reiterates Buy on SCYNEXIS, Maintains $15 Price Target

BenzingaApr 3, 2023 07:28 ET

SCYNEXIS (SCYX) Receives a Buy From Ladenburg Thalmann & Co.

TipRanksApr 3, 2023 06:46 ET